TD Asset Management Inc Has $108.85 Million Stock Holdings in Amgen Inc. $AMGN

TD Asset Management Inc reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 385,720 shares of the medical research company’s stock after selling 20,557 shares during the quarter. TD Asset Management Inc owned about 0.07% of Amgen worth $108,850,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Laurel Wealth Advisors LLC raised its position in shares of Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after purchasing an additional 6,676,575 shares during the period. Norges Bank acquired a new stake in Amgen in the 2nd quarter valued at $1,663,726,000. Vanguard Group Inc. increased its stake in Amgen by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after purchasing an additional 841,117 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Amgen by 5.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after buying an additional 687,735 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Amgen by 248.1% during the second quarter. Jennison Associates LLC now owns 604,774 shares of the medical research company’s stock worth $168,859,000 after buying an additional 431,036 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Truist Financial raised their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Wells Fargo & Company lifted their price target on Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. BMO Capital Markets increased their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Finally, UBS Group raised their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $351.76.

Amgen Trading Up 0.4%

NASDAQ:AMGN opened at $384.33 on Thursday. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $387.49. The firm has a 50-day moving average price of $346.58 and a two-hundred day moving average price of $318.34. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a market cap of $207.18 billion, a price-to-earnings ratio of 27.01, a price-to-earnings-growth ratio of 3.79 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.